MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatment, announced that it has entered into an exclusive option that provides Psycheceutical an opportunity to acquire a majority equity stake in Vici Health Sciences (“Vici”). The total exercise price under the option would be approximately $10.5 million, which would be paid part in cash and part in equity. The Company has until April 2023, unless extended by the parties, to exercise the option. Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.
HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019 (COVID-19).